The role of IL-29 in immunity and cancer

Noah E Kelm; Ziwen Zhu; Vivi A Ding; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang

doi:10.1016/j.critrevonc.2016.08.002

The role of IL-29 in immunity and cancer

Crit Rev Oncol Hematol. 2016 Oct:106:91-8. doi: 10.1016/j.critrevonc.2016.08.002. Epub 2016 Aug 10.

Authors

Noah E Kelm¹, Ziwen Zhu², Vivi A Ding¹, Huaping Xiao³, Mark R Wakefield², Qian Bai², Yujiang Fang⁴

Affiliations

¹ Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, United States.
² Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, United States.
³ Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, United States; The Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China.
⁴ Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, United States; Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, United States. Electronic address: yujiang.fang@dmu.edu.

Abstract

Interleukin-29 (IL-29) is a new member of the recently discovered interferon λ (IFNλ) family. It is produced predominantly by maturing dendritic cells and macrophages. It has been implicated in numerous immunological responses and has shown antiviral activity similar to the Type I interferons, although its target cell population is more limited than the Type I interferons. In recent years, the role of IL-29 in the pathogenesis of various cancers has also been extensively studied. In this review, we will discuss the recent advances of IL-29 in immunological processes and the pathogenesis of various cancer.

Keywords: Cancer; Cytokine; IL-29; Immune response.

Publication types

Review

MeSH terms

Animals
Humans
Interferons
Interleukins / immunology*
Neoplasms / immunology*

Substances

interferon-lambda, human
Interleukins
Interferons